Univariate analysis for progression-free survival and overall survival of biological and clinical parameters for the 45 ALK positive crizotinib-treated patients.

Abbreviation: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; Adeno: adenocarcinoma; SRC: signet ring cell. IHC: immunohistochemistry; ECOG, Eastern Cooperative Oncology Group; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; OS1, overall survival calculated from diagnosis; OS2, overall survival calculated from signed informed consent at the screening time.